Friday, 16 October 2026European Markets

INDLE FIN.ENTREPR. Stock Bullish By 28% In The Last 21 Sessions

Loading stream...

(vianews) - shares of indle fin.entrepr. (cac 40: infe.pa) rose by a staggering 28.43% in 21 sessions from €51 to €65.50 at 02:59 est on monday, after five consecutive sessions in a row of losses. cac 40 is rising 1.87% to €7,270.69, after two sequential sessions in a row of gains.

about indle fin.entrepr.

compagnie industrielle et financière d'entreprises sa operates as a construction company in france. it undertakes maritime and river, underwater, structures and civil engineering, buildings, and other special works. the company also develops real estate properties. compagnie industrielle et financière d'entreprises sa was founded in 1913 and is headquartered in saint-herblain, france. the company is a subsidiary of alfred de musset sas.

earnings per share

as for profitability, indle fin.entrepr. has a trailing twelve months eps of €6.72.

pe ratio

indle fin.entrepr. has a trailing twelve months price to earnings ratio of 9.75. meaning, the purchaser of the share is investing €9.75 for every euro of annual earnings.

volume

today's last reported volume for indle fin.entrepr. is 70 which is 29.41% below its average volume of 34.

more news about indle fin.entrepr. (infe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com